This study describes the development of a novel peptide, 3D-NAF-1 44-67-6K, derived from the human protein CISD2/NAF-1, as a potential treatment for ovarian cancer. The peptide selectively enters ovarian cancer cells, targets their mitochondria, and induces cancer cell death while showing minimal toxicity to healthy cells in laboratory and mouse studies. In mice bearing human ovarian cancer tumors, it significantly reduced the growth of both primary and metastatic tumors. The findings suggest that this peptide could become a new therapy for ovarian cancer, either alone or in combination with existing treatments, and may also have activity against brain and pancreatic cancers.

full article